Invitae: A Menu of Genes

Focus: HEALTHCARE

Briton Ryle Image Briton Ryle Editor, The Wealth Advisory

Invitae Corp (NVTA) first earned a spot on our Top 10 list of best buys back in February, and it hasn’t stopped growing. It’s up about 25% in those two months. Our overall gain in this stock is a whopping 74%! 

And there’s so much more to come. Sales are growing. Costs are shrinking. Potential customer base is expanding exponentially. And competition is practically nonexistent. 

Plus, the company is continuously adding to its test menu of genes (currently 20k). And as of late last month, Invitae offers exome sequencing services. This is huge for patients with a hazy diagnosis but a strong possibility of a genetic disorder. 

It allows doctors to check out a large number of genes at once. And it’s both quick and cost effective. That means it’ll be more likely to get approved and paid for by the insurance companies. 

Management is also partnering with other companies to expand the list of tests available and help diagnose potentially life-threatening disorders. 

I don’t expect to see this growth slowing. And that’s going to lead to NVTA becoming a 100% gain very soon.There’s upside to $20. 

Subscribe to Brit Ryle's The Wealth Advisory here…